GALECTIN THERAPEUTICS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $1.29M, a 6.24% increase year-over-year.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $1.16M.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $853.00K.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $1.22M.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2025 was $3.23M.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2021 was $3.86M, a 8681.82% increase from fiscal 2020.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2020 was $44.00K, a 99.91% decline from fiscal 2019.
- GALECTIN THERAPEUTICS INC. stock issued during period, value, new issues for fiscal 2019 was $47.82M, a 753.45% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $1.29M 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.23M 10-K · filed 2026-03-31 |
| 2025-09-30 | $853.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $1.22M 10-Q · filed 2026-08-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.86M 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $3.86M 10-Q · filed 2022-08-15 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $44.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2020-06-30 | $44.00K 10-Q · filed 2021-08-16 | |
| 2019-12-31 | $902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $47.82M 10-K · filed 2021-03-31 |
| 2019-09-30 | $163.00K 10-Q · filed 2020-11-09 | $46.92M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $44.89M 10-Q · filed 2020-08-10 | $52.00M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $1.86M 10-Q · filed 2020-05-11 | $12.35M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $5.60M 10-K · filed 2020-03-16 |
| 2018-09-30 | $5.24M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $5.24M 10-Q · filed 2019-08-09 | |
| 2017-12-31 | $3.38M 10-K · filed 2019-03-06 | |
| 2016-12-31 | $416.00K 10-K · filed 2018-03-29 | |
| 2015-12-31 | $13.70M 10-K · filed 2017-03-28 | |
| 2014-12-31 | $29.34M 10-K · filed 2016-03-15 | |
| 2014-03-31 | $30.10M derived: 10-Q 165 month − 10-K 162 month · filed 2014-05-13 | $37.03M derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | $833.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $3.83M 10-K · filed 2016-03-15 |
| 2013-09-30 | $6.10M derived: 10-Q 159 month − 10-Q 156 month · filed 2013-11-12 | |
| 2013-06-30 | $0.00 derived: 10-Q 156 month − 10-Q 153 month · filed 2013-08-14 | |
| 2012-12-31 | $68.77M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $68.80M 10-K · filed 2013-03-29 |
| 2012-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |